Addex Reclaims Rights to Phase 2 mGlu2 PAM Asset ADX71149

GENEVA, Switzerland, April 17, 2025 — Addex Therapeutics, a clinical-stage biopharmaceutical company trading under the symbol ADXN on both the SIX Swiss Exchange and NASDAQ, has made a significant announcement concerning the future of one of its key assets, ADX71149 (also known as JNJ-40411813). This development follows the conclusion of its partnership with Janssen Pharmaceuticals, Inc., now operating as J&J Innovative Medicine, which had been collaborating with Addex on the drug's development for epilepsy. The conclusion of this partnership has resulted in Addex regaining all rights to the further development and commercialization of ADX71149.

Tim Dyer, the CEO of Addex Therapeutics, expressed enthusiasm about reclaiming control over ADX71149, highlighting its robust data package and potential for future development. The drug has already completed three Phase 2 studies, demonstrating its promise as a high-quality asset. Dyer emphasized that Addex is currently exploring various high-value therapeutic indications for the drug's future development. Additionally, the company is actively engaging in discussions with potential partners who may be interested in further advancing the program.

Addex Therapeutics is renowned for its commitment to developing small molecule allosteric modulators aimed at treating neurological disorders. The company's lead drug candidate, dipraglurant, which functions as an mGlu5 negative allosteric modulator (NAM), is under consideration for its potential to aid recovery in brain injuries, such as those resulting from strokes or traumatic incidents. Furthermore, Addex's collaboration with Indivior has led to the selection of a GABAB positive allosteric modulator (PAM) for development in addressing substance use disorders. In parallel, Addex is independently pursuing a GABAB PAM program aimed at treating chronic cough.

Addex also maintains a strategic 20% equity stake in Neurosterix LLC, a private enterprise that is advancing its own suite of allosteric modulator programs. These include M4 PAM for schizophrenia, mGlu7 NAM for managing mood disorders, and mGlu2 NAM for addressing mild neurocognitive disorders. The company’s commitment to innovative treatments continues to drive its research and development efforts in these areas.

Addex Therapeutics' shares are accessible to investors on both the SIX Swiss Exchange and the NASDAQ Capital Market, providing a platform for supporting their ambitious projects and research initiatives. With the reacquisition of ADX71149 and ongoing developments in various therapeutic areas, Addex is well-positioned to make significant contributions to the field of neurological therapeutics.